Erasca, Inc.
ERAS · XNASCIK 1761918fmd_1GVMZD6PM6FDG21P3WRV4CAZ1TManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 30 | 74 | 112 | 104 | 115 | 93 |
| Total operating expenses | 109 | 125 | 247 | 142 | 180 | 141 |
| Operating income | (109) | (125) | (247) | (142) | (180) | (141) |
| Other non-operating income (expense) | 8 | 2 | 5 | 16 | 18 | 16 |
| Income before taxes | – | – | – | – | (162) | (125) |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (162) | (125) |
| Net income | (102) | (123) | (243) | (125) | (162) | (125) |